̽»¨¾«Ñ¡

Molecular neurophysiology – Karima Chergui's research group

Our research aims to identify neuronal alterations in models of Parkinson’s disease, focusing on glutamatergic synapses in the basal ganglia. Another important goal of our research is to increase our understanding of the mechanisms that lead to the rapid and long-lasting antidepressant action of ketamine. An important aim of our research is to understand the physiological role of the NMDA type of glutamate receptors and their dysfunctions in diseases that affect the basal ganglia.

Projects

Project 1

NMDA receptors subunits as targets for the treatment of Parkinson’s disease

Parkinson’s disease is characterized by severe motor disturbance which include slowness of movement, rigidity and tremor. Anxiety, depression and anhedonia are also common non-motor symptoms. In Parkinson’s disease, different neuronal populations degenerate progressively, particularly dopamine neurons in the substantia nigra. This neuronal loss leads to a dramatic reduction in the content of dopamine in the striatum, and a resultant imbalance in several neurotransmitter systems in the basal ganglia including glutamatergic neurotransmission. Our research investigates, in models of Parkinson’s disease, if the functions of the NMDA type of glutamate receptors, and their subunit composition, are altered in different neuronal populations of the basal ganglia. An important goal of our research is to determine if the GluN2 subunits of NMDA receptors can be proposed as targets for the treatment of Parkinson’s disease.

Project 2

NMDA and AMPA receptors as targets for the treatment of depression

Low doses of ketamine exert rapid and lasting antidepressant actions in treatment-resistant patients affected by severe depression. Our research aims to better understand how ketamine produces a rapid and lasting antidepressant action and to suggest other therapies for the treatment of depression. We examine the molecular and cellular mechanisms by which ketamine and its metabolites alter glutamatergic transmission and plasticity in brain regions involved in reward-motivated behaviors and in depression. This mesolimbic circuit includes the nucleus accumbens and ventral tegmental area and is involved in reward and motivation, important functions which are impaired in patients with depression. Our studies will allow us to determine if the subunits that compose NMDA receptors and AMPA receptors can be suggested as targets for the development of novel pharmacological tools, with reduced propensity to induce side effects, in the treatment of depression.

Illustration of Karima Chergui's research showing ventral tegmental area (VTA) and the nucleus accumbens (NAc)
From: Yao N, Skiteva O, Zhang X., Svenningsson P and Chergui K. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Molecular Psychiatry, 23(10): 2066-2077, 2018.

Publications

Selected publications

  • Article: NPJ PARKINSONS DISEASE. 2023;9(1):56
    Skiteva O; Yao N; Mantas I; Zhang X; Perlmann T; Svenningsson P; Chergui K
  • Article: BIOMOLECULES. 2022;13(1):51
    Yao N; Skiteva O; Chergui K
  • Article: BIOMOLECULES. 2022;12(11):1635
    Sitzia G; Skiteva O; Chergui K
  • Doctoral thesis: 2022
    Sitzia G
  • Article: SCIENCE ADVANCES. 2022;8(34):eabo1543
    Toskas K; Yaghmaeian-Salmani B; Skiteva O; Paslawski W; Gillberg L; Skara V; Antoniou I; Sodersten E; Svenningsson P; Chergui K; Ringner M; Perlmann T; Holmberg J
  • Article: JOURNAL OF NEUROCHEMISTRY. 2022;161(2):158-172
    Skiteva O; Yao N; Sitzia G; Chergui K
  • Article: TRANSLATIONAL PSYCHIATRY. 2021;11(1):530
    Skiteva O; Yao N; Chergui K
  • Article: NEUROPHARMACOLOGY. 2020;174:108136
    Sitzia G; Mantas I; Zhang X; Svenningsson P; Chergui K
  • Article: MOLECULAR PSYCHIATRY. 2018;23(10):2066-2077
    Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
  • Article: CNS NEUROSCIENCE & THERAPEUTICS. 2018;24(2):144-153
    Nouhi M; Zhang X; Yao N; Chergui K
  • Article: LEARNING & MEMORY. 2016;23(9):479-485
    Zhang X; Yao N; Chergui K
  • Article: NEUROPHARMACOLOGY. 2015;92:108-115
    Zhang X; Chergui K
  • Article: BRITISH JOURNAL OF PHARMACOLOGY. 2014;171(16):3938-3945
    Zhang X; Feng Z-J; Chergui K
  • Article: EXPERIMENTAL NEUROLOGY. 2014;255:154-160
    Feng Z-J; Zhang X; Chergui K
  • Article: JOURNAL OF NEUROCHEMISTRY. 2014;129(4):581-590
    Zhang X; Feng Z-J; Chergui K
  • Article: NEUROPHARMACOLOGY. 2011;60(6):975-981
    Chergui K
  • Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S14-S15
    Zhang X; Chergui K
  • Article: JOURNAL OF NEUROCHEMISTRY. 2008;106(4):1758-1765
    Schotanus SM; Chergui K
  • Article: EUROPEAN JOURNAL OF NEUROSCIENCE. 2008;27(8):1957-1964
    Schotanus SM; Chergui K
  • Article: NEUROPHARMACOLOGY. 2008;54(5):837-844
    Schotanus SM; Chergui K
  • Article: NEUROPHARMACOLOGY. 2006;51(2):272-282
    Schotanus SM; Fredholm BB; Chergui K
  • Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:S17
    Schotanus SM; Chergui K
  • Article: NEUROPHARMACOLOGY. 1999;38(2):223-231
    Chergui K; Lacey MG
  • Show more

Staff and contact

Group leader

All members of the group

Visiting address

̽»¨¾«Ñ¡, Physiology and Pharmacology, Bioclinicum J5:20 Neuro, Visionsgatan 4, Solna, 171 64, Sweden

Postal address

̽»¨¾«Ñ¡, Physiology and Pharmacology, Bioclinicum J5:20, Visionsgatan 4, Solna, 171 64, Sweden

Keywords:
Antidepressive Agents Basal Ganglia Neurophysiology Neurosciences Parkinson Disease Receptors, Ionotropic Glutamate Show all
Content reviewer:
22-03-2024